Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Follow-up data for 11 patients with non-Hodgkin's lymphoma treated with partially purified human leukocyte interferon is presented. The interferon preparation used was 0.1% pure and treatment consisted of 5 x 10(6) U given intramuscularly twice daily for 60 injections. One complete, three partial, and three minimal responses were observed in five of seven evaluable patients with nodular non-Hodgkin's lymphoma. Duration of response appears to be from 6 to 12 mo. One patient achieved a second partial response on retreatment with interferon in spite of having received chemotherapy in the interval between interferon treatments. No responses were seen in three patients with rapidly progressive diffuse histiocytic lymphoma. Dose-limiting toxicity is leukopenia, which necessitated modification or cessation of treatment in three patients. Nonhematologic toxicities consisted of fever, malaise, arthralgia, and loss of appetite. In conclusion, interferon has activity against non-Hodgkin's lymphoma, and prior treatment with chemotherapy does not preclude a response to interferon.
 ...
PMID:Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. 616 19

Interferons are proteins elaborated by infected cells that protect noninfected cells from viral infection. These proteins produce a temporary "antiviral state" by altering nucleotide metabolism and cytoplasmic enzyme induction. Interferons appear early after viral infection locally and systematically to limit spread of viral infection; they also affect cell differentiation, growth, surface, antigen expression, morphologic findings, and immunoregulation. Several human disorders have diminished interferon production. Newborns have normal interferon alpha but deficient interferon gamma production. Infants with congenital infections may also have defects in interferon production. Immunosuppressed patients receiving transplants (marrow, heart, of kidney) have diminished interferon production, particularly immediately after transplant. Deficiencies of interferon have also been noted in Down's syndrome, cellular immunodeficiencies, uremia, malnutrition, and hematopoietic malignancy. Leukocyte interferon has been of therapeutic value in herpes zoster infections, in patients with cancer, and in patients with hepatitis B infection. Interferon has not been proved to help children with congenital cytomegalovirus or rubella. Interferon can shrink lymphoid tumors, particularly non-Hodgkin's lymphoma.
 ...
PMID:UCLA conference. Interferon: immunobiology and clinical significance. 617 66

The effect of interferon treatment on both lymphocyte subpopulation numbers and function was studied in two groups of patients who were being treated systemically with 0.5 to 1.0 x 10(7) units of human leukocyte-derived interferon (HulFN-alpha) daily. Patients with nodular lymphocytic, poorly differentiated non-Hodgkin's lymphoma (NLPD) were given interferon for 30 days and those with chronic hepatitis B infection were treated in cycles for 4 to 7 days. In both patient groups, B lymphocytes numbers were reduced during treatment, but T lymphocyte numbers were unaffected. T lymphocyte responses, measured by blast transformation to herpesvirus antigens were generally low before treatment in NLPD patients. The responses were restored after termination of therapy. In two NLPD patients given two courses of treatment separated by a 3 month interval, the restored T lymphocyte responses were inhibited during the second course of treatment. In patients with chronic hepatitis B virus infection, lymphocyte blast transformation to the viral antigens were also depressed during treatment compared to pretreatment responses. Changes in lymphocyte responses to phytohemagglutinin and pokeweed mitogen were not observed in either patient group.
 ...
PMID:Effect of interferon therapy on circulating lymphocytes in humans. 618 33

We report the results of a trial of recombinant leukocyte A interferon in previously treated patients with non-Hodgkin's lymphoma who were no longer responsive to chemotherapy. Patients received recombinant leukocyte A interferon (50 X 10(6) U per square meter of body-surface area) by intramuscular injection three times weekly for three months or longer. Forty-five patients were enrolled in the study, and 37 were evaluated for a response. Thirteen of 24 (54 per cent) evaluable patients with low-histologic-grade non-Hodgkin's lymphoma had objective responses (nine partial responses and four histologically confirmed complete responses). Two of six (33 per cent) with intermediate-grade lymphoma responded (one partially and one completely), and one of seven (14 per cent) with high-grade lymphoma had a partial response. The median duration of responses was eight months. Four of the five complete responders have continued to receive maintenance interferon and have been in complete remission for 3, 7, 9, and 12 months, respectively; one had a recurrence at a site of previous disease seven months after interferon had been stopped. Side effects were noted in most patients. All 16 responders had been heavily pretreated with combination chemotherapy, including doxorubicin in 8 of the 16. These results suggest that recombinant leukocyte A interferon may be an effective new therapy for some patients with low- and intermediate-grade non-Hodgkin's lymphoma.
 ...
PMID:Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. 648 33

Four patients with adult T-cell leukemia (ATL) and 4 patients with non-Hodgkin's lymphoma were treated with alpha-type interferon (Human Lymphoblastoid Interferon: HLBI). Treatment regimen consisted of 3 to 12 million units (MU) of HLBI given intramuscularly once daily. The total dose varied from 36 to 520 MU. Complete remissions were obtained in one of 4 patients with ATL and one of 3 patients with B-cell lymphoma. A partial remission was yielded in one patient with B-cell lymphoma. An overall response rate (CR + PR) was 37.5%. Toxicity included flu-like symptoms, myelosuppression, G-I tract symptoms, fatigue, high fever and hepatic disturbance. On the basis of this study, we have concluded that HLBI is effective for the treatment of ATL and B-cell lymphoma.
 ...
PMID:[Effect of human lymphoblast interferon in adult T-cell leukemia and non-Hodgkin's lymphoma]. 660 14

Eighty-one patients with a variety of refractory disseminated malignant neoplasms have been treated in the first multiple fixed-dose phase I trial of recombinant leukocyte A interferon (IFL-rA). Each patient received IFL-rA by intramuscular injection, three times weekly for 28 days. Dosages were escalated in different patients from 1 to 136 x 10(6) units per injection. The toxic reactions seen with IFL-rA resembled those of nonrecombinant leukocyte interferon and included fever, chills, fatigue, anorexia, myalgia, headache, occasional nausea and vomiting, and dose-dependent reversible leukopenia and hepatic transaminase elevations. The pharmacokinetics of IFL-rA were also comparable with nonrecombinant leukocyte interferon. Objective evidence of antitumor activity was seen in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease, breast cancer, and melanoma, indicating that IFL-rA, the first genetically engineered biological response modifier available for testing in cancer patients, is biologically active in vivo.
 ...
PMID:A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. 675 47

Studies were undertaken to determine whether leukemia and lymphoma cells would be lysed by autologous and allogeneic interferon (IFN) activated peripheral blood mononuclear cells (PBMC). PBMC from healthy donors and from patients were cultured with and without 500 U of highly purified human fibroblast IFN/ml for 24 hr, and then their cytotoxic activity was assayed by a 5-hr 51Cr-release test. Of primary tumor cells isolated from patients, the cells of 5 of 15 patients with acute nonlymphocytic leukemia (ANLL), 5 of 9 patients with acute lymphocytic leukemia (ALL), 2 of 3 patients with chronic phase chronic myelogenous leukemia (CML), 2 of 3 patients with blastic phase CML, 1 patient with hairy cell leukemia, and 6 patients with diffuse non-Hodgkin's lymphoma were sensitive to IFN-activated PBMC of healthy donors, whereas the cells of 3 of the ANLL patients, 2 of the ALL patients, and 3 of the lymphoma patients were sensitive to unstimulated PBMC. Of the ANLL cells tested, myeloblasts, promyelocytes, and monoblasts were sensitive to either unstimulated or IFN-activated PBMC. Compared with the ANLL cells, the lymphoma cells were statistically significantly sensitive to activated effector cells (p less than 0.025). On the basis of the unlabeled target competition test and the recovery of cytotoxic cells within the fractions enriched in natural killer (NK) cells, NK cells appeared to mediate the above unstimulated and IFN-boosted cytotoxicity. In experiments using autologous effector-target cells from 11 patients, the addition of 500 U of IFN/ml enhanced the lytic activity of PBMC against autologous lymphoma cells in 1 patient, and higher concentrations of IFN, i.e., 2500 or 3500 U/ml, enhanced their cytotoxic activity against autologous leukemia or lymphoma cells in 4 of 8 patients. These data indicate that IFN-activated allogeneic PBMC are able to lyse both myeloid and lymphoid tumor cells, whereas higher concentrations of IFN are required to enhance lytic activity against autologous tumor cells.
 ...
PMID:Lysis of leukemia and lymphoma cells by autologous and allogeneic interferon-activated blood mononuclear cells. 683 Oct 42

A substantial proportion (44%) of peripheral blood lymphocyte samples from 41 patients with malignant lymphoma have been shown to have depressed or undetectable levels of natural cytotoxicity against the leukaemic cell line K562 in a 4-hr [51Cr]-release assay. No correlation was found between low levels of natural killer (NK) cell activity and either the age of the patients, total or differential white blood counts, or the type or stage of disease. Furthermore, pre-treatment of lymphocytes with human lymphoblastoid (Namalva) interferon failed to enhance NK levels in 5/11 patients with Hodgkin's disease and 5/8 patients with non-Hodgkin's lymphoma, and was in contrast to the response of control peripheral blood lymphocytes assayed under the same test conditions. The lack of responsiveness to interferon of peripheral blood NK cells from lymphoma patients was not wholly associated with those patients shown to have low levels of spontaneous NK activity.
 ...
PMID:Depressed spontaneous natural killing and interferon augmentation in patients with malignant lymphoma. 689 51

Human fibroblast interferon(HFIF) was used in 26 patients with various malignant diseases, most of whom had previous chemotherapy. The dosages used were 3 X 10(6) IU or 6 X 10(6) IU of HFIF i. v. daily. Out of 24 evaluable patients, there were 2 partial remissions (CLL 1 and multiple myeloma 1), and 7 stable diseases (multiple myeloma 2, stomach cancer 2, non-Hodgkin's lymphoma 1, CLL 1 and malignant melanoma 1). The majority of the patients experienced fever exceeding 38 degrees C and chills, which became uncommon within several days of treatment. Other side effects included myelosuppression, general malaise, anorexia, hepatic dysfunction and renal dysfunction, which were mild and tolerable.
 ...
PMID:[Clinical effects of human fibroblast interferon on malignant tumors]. 718 62

Initially discovered as antiviral agents, the interferons (IFNs) proved to be a class of cytokines with multifunctional properties, including inhibition of cell growth and modulation of immune functions. A number of clinical trials were thus carried out in cancer and viral diseases, and IFN-alpha therapy was shown to have a wide range of indications in hematology and dermatology: B-cell malignancies (hairy cell leukemia, non-Hodgkin's lymphoma, multiple myeloma), myeloproliferations (chronic myeloid leukemia, thrombocytosis), cutaneous T lymphoma, basal-cell carcinoma, cutaneous squamous cell carcinoma, Kaposi's sarcoma. IFN therapy also showed efficacy in viral tumors (condyloma acuminatum and laryngeal papillomatosis) and chronic hepatitis B and C. The antitumoral action of IFN-alpha mainly involves its capacity to inhibit cell proliferation, partly via antagonistic effects on growth factors. The elucidation of IFN-alpha signalling pathway(s) leading to gene activation, a better understanding of the interactions between IFN-alpha and cytokine network, and the development of combination therapy with other biological treatments or chemotherapy should greatly improve the clinical use of IFNs.
 ...
PMID:[Interferons, a class of cytokines with a large therapeutic activity range]. 751 33


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>